← Human Trials & Peer-Reviewed Studies
Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trial
Plain-language guide to PMID 40974403 (2025): randomized controlled trial study of Teriparatide in 70 women.
Key Facts
- PMID
- 40974403
- Journal
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Dash AS et al. (5 authors)
- DOI
- 10.1007/s00198-025-07696-7
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide, published as a randomized controlled trial.
The osteoanabolic effects of teriparatide are maximal in the first 6 months of treatment.
The effects of teriparatide (TPTD) are maximal in the first 6 months when bone formation exceeds resorption to the greatest degree.
Who Took Part
According to the abstract, 70 women were involved.
PubMed indexes the participants as middle-aged adults, older adults and people over 80, women only.
70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32).
DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.
A time span of 18 months appears in the methods.
What Was Measured
The effects of teriparatide (TPTD) are maximal in the first 6 months when bone formation exceeds resorption to the greatest degree.
Topics PubMed links to this paper include Absorptiometry, Photon, Bone Density, Bone Density Conservation Agents, Cancellous Bone, Denosumab, Lumbar Vertebrae and Osteoporosis, Postmenopausal.
The authors tagged it with the keywords Clinical trials, DXA, TBS and Teriparatide.
What This Means in Plain Language
The paper is a randomized study of Teriparatide in 70 women over 18 months.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2025 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.